Products for Research Use Only
RegisterLogin

Everolimus-13C2, d4

CAT: 0804-HY-10218S1Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10218S1Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Everolimus-13C2, d4 (RAD001-13C2, d4) is 13C labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities[1][2].
CAS Number
1661009-29-5
Product Name Alternative
RAD001-13C2, d4; SDZ-RAD-13C2, d4
UNSPSC
12352211
Target
Apoptosis; Autophagy; Bacterial; FKBP; Isotope-Labeled Compounds; mTOR
Related Pathways
Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; Others; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
O=C1N2[C@](CCCC2)([H])C(O[C@](CC([C@@H](/C=C([C@H]([C@H](C([C@@H](C[C@@H](/C=C/C=C/C=C([C@H](C[C@@]3([H])O[C@@](C1=O)([C@@H](CC3)C)O)OC)\C)C)C)=O)OC)O)\C)C)=O)([H])[C@H](C)C[C@H]4C[C@H]([C@@H](CC4)O[13C]([2H])([2H])[13C]([2H])([2H])O)OC)=O
Molecular Formula
C51 13C2H79D4NO14
Molecular Weight
964.23
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Kawata T, et al. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia. Cancer Sci. 2018 Jan;109 (1) :103-111.|[3]Zhu Y, et al. Antitumor effect of the mTOR inhibitor Everolimus on human breast cancer stem cells in vitro and in vivo. Tumour Biol. 2012 Oct;33 (5) :1349-62.|[4]Lane HA, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res, 2009, 15 (5), 1612-1622.|[5]O'Reilly T, et al. Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001) : Processes, Limitations, and Further Proposals. Transl Oncol. 2010 Apr;3 (2) :65-79.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-10218S-01Everolimus-d4
HY-B0579S3Cyclosporin A-13C2, d4
HY-14749AS1Pyronaridine-13C2, d4 (tetraphosphate)
HY-167810ACyclosporin A Acetate-13C2, d4
HY-W754548Glycocholic acid-13C2, d4
HY-10218-01Everolimus
HY-10218R-01Everolimus (Standard)
HY-W006057AS3-01Sodium 3-methyl-2-oxobutanoate-13C2, d4
HY-W588192S1-Methyl-5- (3-pyridinyl) -2-pyrrolidinone-13C2, d4
HY-B0141S5Estradiol-13C2

Alternative Products

CatalogName
RM-E221332-01Everolimus-13C2,2H4
AR-E02255-01Everolimus-13C2-d4
449864-01Everolimus-13C2, D4 discontinued
FE23209-01Everolimus

Popular Products